Pilatus Biosciences Inc. Receives Orphan Drug Designation from FDA for PLT012 in Treatment of Liver and Intrahepatic Bile Duct Cancer
We are honored to receive Orphan Drug Designation for PLT012, a milestone that reflects our dedication to addressing the urgent need for innovative therapies in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
PLT012 leverages metabolic checkpoint targeting to reprogram the Tumor Microenvironment (TME), offering a unique therapeutic approach. This designation highlights the promising scientific discoveries and results we have achieved in addressing the underserved area.
It further motivates us to accelerate PLT012’s development and collaborate globally to bring this promising treatment to patients with limited options.
Dr. sc. ETH Zürich.
2 个月Great news!!!
President
3 个月??Congrats!
Biomedical M&A, BD&L and Investments; Board Roles
3 个月Nice going Raven, all the best!
Partner (IP transactions) - Life sciences, digital health, technology
3 个月Fantastic news.
TJ Biopharma - VP of Corporate Development
3 个月Congrats Raven!